Revolutionary Gene Therapy Cures Inherited Blindness in Clinical Trial

In a landmark clinical trial, researchers at the University of Oxford and Moorfields Eye Hospital have successfully used gene therapy to restore vision in patients with inherited retinal dystrophy, a condition that causes progressive vision loss and eventual blindness.

The therapy, designated "RetinaFix," uses a modified virus to deliver a healthy copy of the defective gene directly into the photoreceptor cells of the retina. In the Phase 3 trial involving 120 patients, 94% showed significant improvement in vision within six months, with 67% achieving 20/40 vision or better.

"Reading the letters on an eye chart for the first time, seeing a loved one's face clearly — these are moments I will never forget," said one trial participant. "This therapy has given me back my independence and my future."

The treatment is expected to receive regulatory approval within the next year, with plans to expand the approach to other genetic eye conditions. The research team is also exploring applications for age-related macular degeneration, which affects millions of elderly people worldwide.